fig4

Figure 4. Outcome of complete and differential blood count and immunophenotyping during chemo-immunotherapy and salvage chemotherapy. A: The blood count showed an initial increase in white blood cells (WBC), neutrophilic granulocytes (N) and lymphocytes (Lym) followed by their decrease during chemo-immunotherapy; B: An undulating trend of CD3⁺, CD4⁺, CD8⁺, CD19⁺, CD16⁺, HLA-DR⁺ and Tregs and a transient decrease in Treg count were observed after chemo-immunotherapy. Subsequently, after an increase in Treg count, there was a decrease during chemotherapy. CD3⁺: cluster of differentiation 3 T cell; CD4⁺: CD4⁺ (helper) T cell; CD8⁺: CD8⁺ (cytotoxic) T cells; CD19⁺: cluster of differentiation 19 B-lymphocyte; CD16⁺: type I transmembrane receptor mediating antibody-dependent cellular cytotoxicity (ADCC) by NK cells; HLA-DR⁺: histocompatibility class II allele T cell; Treg: regulatory T cells CD4(+)CD25(+)Foxp3(+)